Shanghai Hope Medicine Closes $56 Million for Novel Drug Development

Shanghai Hope Medicine closed a $56 million Series B round led by Qiming Venture Partners and Grand Flight Investment. HopeMed is a global novel biopharma with R&D bases in Nanjing ,  Shanghai and  Beijing , It plans to develop products from internal R&D and in-licensings. The company was founded by Professor Rui-Ping Xiao, the dean of the College of Future Technology of Peking University, and an associate editor of New England Journal of Medicine. HopeMed focuses on three areas: women's health, endocrine and cardiovascular diseases. More details.... Share this with colleagues: // //